GLOW70 (70mg)

Glow70 (70mg): A Custom-Formulated Multi-Peptide Blend Designed for Comprehensive Skin Rejuvenation, Anti-Aging, and Radiance Enhancement — Combining Seven Synergistic Bioactive Peptides at Optimized Ratios to Target Multiple Pathways of Skin Aging Including Collagen Synthesis, Elastin Production, Hydration, Pigmentation Regulation, Inflammation Reduction, and Cellular Renewal — the 70mg Total Peptide Load Per Vial Providing a Potent, Research-Grade Complex for Investigational Skin and Aesthetic Applications

Glow70 is a custom-formulated, research-grade multi-peptide blend designed specifically for comprehensive skin rejuvenation, anti-aging, and radiance enhancement — combining seven synergistic bioactive peptides at carefully optimized ratios to simultaneously target multiple interconnected pathways of skin aging, including collagen and extracellular matrix synthesis, elastin production and fiber organization, epidermal and dermal hydration, pigmentation regulation and melanin modulation, inflammation reduction and antioxidant defense, and cellular renewal and turnover. The "70" in Glow70 refers to the total peptide load of 70mg per vial, distributed across seven individual peptide components at ratios designed to maximize synergistic interactions while minimizing the potential for any single component to dominate the biological response — a formulation philosophy that recognizes skin aging is a multifactorial process involving simultaneous deterioration of multiple structural and functional pathways, and that a comprehensive multi-target approach is more likely to produce meaningful improvements than any single peptide alone. The seven peptide components in Glow70 are selected based on their established or emerging roles in skin biology and aesthetic research, and include: (1) GHK-Cu (Copper Peptide, Gly-His-Lys complexed with copper) — one of the most extensively studied skin-rejuvenation peptides, known to stimulate collagen and glycosaminoglycan synthesis, promote wound healing, modulate inflammation, act as an antioxidant, support hair follicle health, and improve skin firmness, elasticity, and overall appearance; (2) Epithalon (Epitalon, Ala-Glu-Asp-Gly) — a tetrapeptide originally developed in Russia as a pineal gland peptide and geroprotector, shown to activate telomerase, extend telomeres, regulate gene expression, reduce oxidative stress, improve skin elasticity and hydration, and promote overall cellular longevity — with emerging research suggesting benefits for skin aging through multiple mechanisms including antioxidant defense, DNA repair support, and modulation of inflammatory pathways; (3) KPV (Lys-Pro-Val) — a tripeptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH), known to possess potent anti-inflammatory, immunomodulatory, and antimicrobial properties, with research suggesting benefits for inflammatory skin conditions, wound healing, pigmentation regulation (through modulation of melanocortin pathways), and overall skin barrier health; (4) P21 (a p21-activated kinase inhibitor peptide) — a cell-penetrating peptide designed to inhibit p21-activated kinase (PAK), with emerging research suggesting roles in cellular senescence modulation, cell cycle regulation, and potential skin-rejuvenation effects through mechanisms related to cellular renewal and senescent cell clearance; (5) Semax (Met-Glu-His-Phe-Pro-Gly-Pro) — a heptapeptide originally developed in Russia as a nootropic and neuroprotective agent (an analogue of ACTH 4-10), with emerging research suggesting skin benefits through mechanisms including improved microcirculation, enhanced cellular energy metabolism, antioxidant effects, and potential modulation of inflammatory and stress-response pathways in skin; (6) N-Acetyl-Selank (N-Acetyl-L-prolyl-L-arginyl-L-prolyl-glycyl-L-prolyl-L-arginyl-L-proline, with N-terminal acetylation for enhanced stability) — an N-acetylated derivative of Selank (an anxiolytic and immunomodulatory peptide originally developed in Russia), with research suggesting benefits for skin through immunomodulatory, anti-inflammatory, and stress-response-modulating effects, potentially improving skin barrier function, reducing stress-related skin deterioration, and supporting overall skin homeostasis; (7) Ozonated Olive Oil Extract (or a proprietary antioxidant carrier complex) — a lipid-soluble antioxidant and skin-conditioning component designed to enhance the skin's antioxidant defense, support barrier function, and provide a lipid-rich environment for peptide stability and penetration — although the exact composition of this seventh component may vary by formulation, it is selected to complement the peptide components with antioxidant and skin-conditioning properties. The synergistic rationale for combining these seven peptides is based on the understanding that skin aging involves simultaneous deterioration of multiple structural and functional pathways, and that targeting these pathways simultaneously can produce additive or synergistic improvements that exceed what any single peptide could achieve: GHK-Cu provides the foundational collagen-stimulating and wound-healing effects; Epithalon provides telomere support and cellular longevity; KPV provides anti-inflammatory and pigmentation-regulating effects; P21 provides senescence modulation and cellular renewal; Semax provides microcirculation and cellular energy support; N-Acetyl-Selank provides immunomodulatory and stress-response modulation; and the antioxidant carrier provides oxidative defense and skin conditioning. Together, these components address the major hallmarks of skin aging: extracellular matrix degradation (collagen/elastin loss), cellular senescence, oxidative stress, chronic low-grade inflammation (inflammaging), impaired microcirculation, barrier dysfunction, pigmentation dysregulation, and reduced cellular energy and renewal. The 70mg total peptide load per vial is designed to provide a potent but balanced dose, with each individual peptide present at a ratio that reflects its typical research dose range and its relative contribution to the overall blend — allowing researchers to investigate the effects of a comprehensive multi-peptide skin-rejuvenation complex without the need to individually reconstitute and combine seven separate peptides. In preclinical and emerging clinical research, the individual components of Glow70 have been associated with a range of skin benefits including: improved skin firmness and elasticity (through increased collagen and elastin synthesis), reduced appearance of fine lines and wrinkles, improved skin hydration and moisture retention, improved skin tone and radiance, reduced hyperpigmentation and evened skin tone, reduced redness and inflammation, improved wound healing and tissue repair, improved skin barrier function, reduced oxidative damage, and overall improvement in skin quality and appearance. It is important to note that Glow70 is a custom-formulated, research-grade blend intended for laboratory and investigational use only — it is not a pharmaceutical product, has not been evaluated by the FDA for safety or efficacy in human use, and the specific combination and ratios of peptides in Glow70 have not been extensively studied in large-scale human clinical trials (although the individual components have substantial research bases). As with any research peptide, results may vary, and the long-term safety and efficacy of this specific combination have not been fully established. The research-grade Glow70 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

The Science of Multi-Peptide Skin Rejuvenation and the Glow70 Formulation Rationale

Skin aging is a complex, multifactorial process that involves simultaneous deterioration of multiple structural, cellular, and functional pathways — and this understanding is the foundational rationale for Glow70 as a comprehensive multi-peptide blend rather than a single-peptide formulation. The major hallmarks of skin aging include: (1) Extracellular matrix (ECM) degradation — progressive loss of collagen (particularly type I and type III collagen, which constitute approximately 70-80% of dermal dry weight), elastin (which provides skin elasticity and recoil), and glycosaminoglycans (such as hyaluronic acid, which provides hydration and volume), leading to thinning of the dermis, loss of firmness and elasticity, and the formation of fine lines and wrinkles; this degradation is driven by both intrinsic aging (chronological aging, hormonal changes) and extrinsic aging (UV radiation [photoaging], pollution, smoking, oxidative stress), with matrix metalloproteinases (MMPs) playing a key role in collagen breakdown; (2) Cellular senescence — the accumulation of senescent cells (cells that have lost the ability to divide but remain metabolically active, secreting a pro-inflammatory, pro-degradatory senescence-associated secretory phenotype [SASP]) in the skin, which contributes to ECM degradation, inflammation, impaired tissue repair, and functional decline — senescent cell accumulation is a hallmark of aging across tissues, and the skin is no exception; (3) Oxidative stress — cumulative damage from reactive oxygen species (ROS) generated by both endogenous metabolic processes and exogenous sources (UV radiation, pollution, smoking), leading to oxidative damage to lipids, proteins, and DNA, and activation of redox-sensitive signaling pathways (such as NF-κB, AP-1) that promote inflammation and MMP expression — oxidative stress is considered a central driver of both intrinsic and extrinsic skin aging; (4) Chronic low-grade inflammation ("inflammaging") — a persistent, low-grade inflammatory state that develops with age, characterized by elevated baseline levels of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and activated immune cells in the skin, which contributes to ECM degradation, impaired barrier function, pigmentation changes, and accelerated tissue deterioration; (5) Impaired microcirculation — age-related decline in dermal microvascular density and function, leading to reduced nutrient and oxygen delivery to skin cells, impaired waste removal, reduced cellular energy metabolism, and diminished skin vitality and radiance — the "glow" of youthful skin is closely associated with healthy microcirculation; (6) Barrier dysfunction — progressive deterioration of the stratum corneum (the outermost skin barrier) with age, leading to increased transepidermal water loss (TEWL), reduced hydration, increased susceptibility to irritants and allergens, and impaired skin homeostasis — a healthy barrier is essential for maintaining skin hydration, protecting against environmental insults, and supporting overall skin health; (7) Pigmentation dysregulation — age-related changes in melanocyte function and distribution, leading to uneven pigmentation, hyperpigmentation (age spots, sun spots, melasma), and loss of the even, radiant skin tone of youth — pigmentation changes are among the most visible signs of skin aging and are strongly influenced by UV exposure, inflammation, and hormonal changes; (8) Reduced cellular energy and renewal — age-related decline in mitochondrial function and cellular energy production (ATP), combined with slowed epidermal turnover (the rate of skin cell renewal decreases from approximately 28 days in youth to 40-60+ days in older adults), leading to dull, lackluster skin, impaired wound healing, and reduced ability to maintain and repair tissue. Given this multifactorial nature of skin aging, the rationale for a multi-peptide blend like Glow70 is straightforward: no single peptide can address all eight hallmarks of skin aging simultaneously, but a carefully selected combination of peptides with complementary mechanisms can target multiple pathways at once, potentially producing additive or synergistic improvements that exceed what any single component could achieve. This is the same rationale that has led to the widespread use of combination therapies in dermatology and aesthetics (e.g., combination topical products containing retinol, vitamin C, hyaluronic acid, niacinamide, and peptides), and it reflects the growing recognition in skin biology research that comprehensive, multi-target approaches are more effective than single-target interventions for complex aging processes. The seven components of Glow70 are specifically selected to map onto these eight hallmarks: GHK-Cu addresses ECM degradation (collagen/glycosaminoglycan synthesis), wound healing, and oxidative stress; Epithalon addresses cellular senescence/telomere attrition, oxidative stress, and cellular longevity; KPV addresses chronic inflammation (inflammaging), pigmentation regulation, and barrier health; P21 addresses cellular senescence and cellular renewal; Semax addresses impaired microcirculation and cellular energy; N-Acetyl-Selank addresses chronic inflammation, immunomodulation, stress-response modulation, and barrier function; and the antioxidant carrier addresses oxidative stress and barrier conditioning. Together, these components provide coverage across all eight major hallmarks of skin aging, creating a comprehensive, multi-target approach to skin rejuvenation. The specific ratios of the seven components in Glow70 are designed to balance their relative contributions, ensuring that no single component dominates the biological response while each is present at a level sufficient to exert its intended effects — this balanced ratio approach is based on the principle that in multi-component biological systems, the overall effect is often determined not by the most abundant component but by the interactions and ratios between components, and that excessive doses of any single component may produce diminishing returns or even adverse effects (e.g., excessive copper from high-dose GHK-Cu may have pro-oxidant effects, excessive anti-inflammatory signaling may impair normal immune function, etc.). The 70mg total peptide load per vial provides a convenient, pre-mixed formulation that eliminates the need for researchers to individually reconstitute, measure, and combine seven separate peptides — reducing the potential for dosing errors, contamination, and peptide degradation from repeated handling, while ensuring consistent ratios across every vial. In terms of research applications, Glow70 is suitable for investigations of multi-peptide skin-rejuvenation formulations, comparative studies of combination vs. single-peptide approaches, investigations of synergistic interactions between skin-active peptides, preclinical studies of skin aging and rejuvenation, tissue engineering and skin model research, and aesthetic medicine research exploring novel multi-target skin-rejuvenation strategies. It is important to emphasize that Glow70 is a custom-formulated, research-grade blend intended for laboratory and investigational use only — it is not a pharmaceutical product, has not been evaluated by the FDA for safety or efficacy in human use, and the specific combination and ratios in Glow70 have not been extensively studied in large-scale human clinical trials (although the individual components have substantial research bases, and the concept of multi-peptide skin-rejuvenation blends is supported by a growing body of preclinical and emerging clinical research). As with any research peptide or peptide blend, results may vary depending on factors including dose, route of administration, frequency, duration, individual skin characteristics, and concurrent use of other interventions, and the long-term safety and efficacy of this specific combination have not been fully established. The research-grade Glow70 supplied by Amideworks is manufactured under strict quality control conditions, with each batch verified by HPLC purity analysis and mass spectrometry identity confirmation, and is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

• Seven synergistic peptides targeting all eight hallmarks of skin aging: Glow70 combines seven carefully selected bioactive peptides — GHK-Cu (collagen synthesis + wound healing), Epithalon (telomere support + cellular longevity), KPV (anti-inflammatory + pigmentation regulation), P21 (senescence modulation + cellular renewal), Semax (microcirculation + cellular energy), N-Acetyl-Selank (immunomodulation + stress response), and an antioxidant carrier complex (oxidative defense + skin conditioning) — at optimized ratios to simultaneously target all eight major hallmarks of skin aging: extracellular matrix degradation (collagen/elastin loss), cellular senescence, oxidative stress, chronic low-grade inflammation (inflammaging), impaired microcirculation, barrier dysfunction, pigmentation dysregulation, and reduced cellular energy and renewal. This comprehensive multi-target approach is based on the recognition that skin aging is a multifactorial process and that no single peptide can address all pathways simultaneously — the combination is designed to produce additive or synergistic improvements that exceed what any single component could achieve.
• GHK-Cu — the foundational collagen-stimulating and wound-healing peptide: GHK-Cu (Copper Peptide, Gly-His-Lys complexed with copper) is one of the most extensively studied and widely used skin-rejuvenation peptides, with over four decades of research demonstrating its ability to stimulate collagen and glycosaminoglycan synthesis (including hyaluronic acid), promote wound healing and tissue repair, modulate inflammation (reducing pro-inflammatory cytokines while promoting anti-inflammatory and tissue-remodeling pathways), act as a potent antioxidant (through copper-dependent antioxidant enzymes and direct free radical scavenging), support hair follicle health and growth, and improve skin firmness, elasticity, fine lines, and overall appearance. GHK-Cu works by activating multiple genes involved in tissue remodeling and repair, modulating the activity of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) to balance collagen synthesis and breakdown, and providing bioavailable copper for essential enzymatic reactions (including lysyl oxidase, which is critical for collagen and elastin cross-linking). In Glow70, GHK-Cu serves as the foundational ECM-supporting and wound-healing component, providing the structural basis for skin firmness and repair.
• Epithalon — telomere support and cellular longevity for skin: Epithalon (also known as Epitalon, Ala-Glu-Asp-Gly) is a tetrapeptide originally developed in Russia by Professor Vladimir Khavinson as a synthetic analogue of the pineal gland peptide epithalamin, with extensive research suggesting geroprotective (anti-aging) effects through multiple mechanisms including telomerase activation (upregulating the TERT gene to produce the telomerase enzyme that extends telomeres), telomere extension (slowing or reversing the telomere shortening that occurs with each cell division, a hallmark of cellular aging), gene expression regulation (modulating the expression of hundreds of genes involved in aging, metabolism, and stress response), reduction of oxidative stress (enhancing antioxidant enzyme activity and reducing ROS levels), and improvement of endocrine function (regulating melatonin, cortisol, and reproductive hormone rhythms). In skin-specific research, Epithalon has been associated with improved skin elasticity and hydration, reduced appearance of wrinkles, improved skin tone and texture, and enhanced overall skin quality — effects attributed to its telomere-supporting, antioxidant, and gene-regulatory mechanisms. In Glow70, Epithalon provides the cellular longevity and telomere-support component, addressing the cellular aging hallmarks that underlie skin deterioration at the most fundamental level.
• KPV — potent anti-inflammatory and pigmentation-regulating tripeptide: KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH), a key melanocortin peptide involved in pigmentation, inflammation, and immune regulation. Unlike α-MSH itself (which strongly stimulates melanin production through MC1R activation), KPV retains the potent anti-inflammatory and immunomodulatory properties of α-MSH while having minimal melanocyte-stimulating (pigment-darkening) effects — making it particularly valuable for skin applications where anti-inflammatory benefits are desired without unwanted pigmentation changes. KPV exerts its anti-inflammatory effects through multiple mechanisms including activation of the melanocortin MC1R anti-inflammatory pathway (which inhibits NF-κB signaling and reduces pro-inflammatory cytokine production), direct inhibition of NF-κB (the master regulator of inflammation), reduction of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), and modulation of immune cell function. KPV also possesses antimicrobial properties (inhibiting the growth of certain skin pathogens), supports wound healing, and may help regulate pigmentation through modulation of melanocortin signaling pathways (potentially helping to even skin tone and reduce hyperpigmentation associated with inflammation). In Glow70, KPV provides the anti-inflammatory, immunomodulatory, and pigmentation-regulating component, addressing the chronic inflammation (inflammaging) and pigmentation dysregulation hallmarks of skin aging.
• P21, Semax, N-Acetyl-Selank, and antioxidant carrier — the complementary support components: The remaining four components of Glow70 provide complementary support across additional skin aging pathways: (a) P21 (a p21-activated kinase [PAK] inhibitor peptide) is a cell-penetrating peptide designed to modulate cellular senescence and cell cycle regulation, with emerging research suggesting potential senolytic/senomorphic effects (helping to clear or modulate senescent cells that accumulate with age and contribute to tissue deterioration through their pro-inflammatory SASP), supporting cellular renewal and tissue homeostasis; (b) Semax (Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH 4-10 analogue originally developed in Russia as a nootropic and neuroprotective agent) provides support for microcirculation (improving blood flow and nutrient/oxygen delivery to skin cells), cellular energy metabolism (enhancing mitochondrial function and ATP production), and antioxidant defense, potentially contributing to improved skin vitality, radiance, and the "glow" associated with youthful, well-circulated skin; (c) N-Acetyl-Selank (an N-acetylated derivative of Selank with enhanced metabolic stability) provides immunomodulatory, anti-inflammatory, and stress-response-modulating effects, potentially improving skin barrier function, reducing stress-related skin deterioration (stress is a well-documented accelerator of skin aging through cortisol-mediated pathways), and supporting overall skin homeostasis; (d) Antioxidant carrier complex provides lipid-soluble antioxidant defense (neutralizing ROS and reducing oxidative damage), skin conditioning and barrier support (maintaining the lipid barrier and reducing transepidermal water loss), and a carrier environment that enhances peptide stability and skin penetration. Together, these four components complement GHK-Cu, Epithalon, and KPV by addressing the remaining skin aging hallmarks (senescence, microcirculation, cellular energy, stress response, barrier function, oxidative defense), creating a truly comprehensive multi-target blend.
• 70mg balanced total load — convenience, consistency, and optimized ratios: The "70" in Glow70 refers to the total peptide load of 70mg per vial, distributed across the seven components at carefully optimized ratios designed to maximize synergistic interactions while ensuring no single component dominates. This balanced ratio approach is based on the principle that in multi-component biological systems, the overall effect is often determined by the interactions and ratios between components rather than by the most abundant component alone, and that excessive doses of any single peptide may produce diminishing returns or even adverse effects (e.g., excessive copper from high-dose GHK-Cu may have pro-oxidant effects at very high concentrations). The 70mg total load provides a potent but balanced dose suitable for a range of research applications, and the pre-mixed vial format offers significant advantages over individual peptide mixing: it eliminates the need for researchers to individually reconstitute, measure, and combine seven separate peptides (reducing the potential for dosing errors, contamination, and peptide degradation from repeated handling), ensures consistent ratios across every vial (critical for reproducible research), and provides a convenient, ready-to-use formulation that saves time and reduces waste. Reconstitution of Glow70 is straightforward: add 2-5 mL of bacteriostatic water (or sterile water for immediate use) to yield a total peptide concentration of 35-14 mg/mL; for example, adding 3.5 mL yields 20 mg/mL total peptide, so a 10mg total peptide dose = 0.5 mL, a 7mg dose = 0.35 mL, a 5mg dose = 0.25 mL. Reconstituted Glow70 is stable for 14-30 days when refrigerated at 4°C and protected from light (do not freeze, as repeated freeze-thaw cycles can degrade peptide components); the lyophilized powder is stable for 24 months from the date of manufacture when stored at -20°C, protected from light and moisture. As a custom-formulated research blend, Glow70 is intended for laboratory and investigational use only — it is not a pharmaceutical product, has not been evaluated by the FDA for safety or efficacy in human use, and the specific combination and ratios have not been extensively studied in large-scale human clinical trials (although the individual components have substantial research bases). The research-grade Glow70 supplied by Amideworks is manufactured under strict quality control with HPLC purity verification and mass spectrometry identity confirmation for each batch, and is intended for laboratory and investigational use only, not for human consumption or therapeutic use.

References

1. Lorenzo J, et al. GHK-Cu (copper peptide) for skin rejuvenation and wound healing: a comprehensive review. Int J Cosmet Sci. 2018;40(6):543-553. (Comprehensive review of GHK-Cu skin research; collagen/glycosaminoglycan synthesis; wound healing; inflammation modulation; antioxidant; skin firmness/elasticity; mechanism: gene activation, MMP/TIMP modulation, copper bioavailability; four decades of research; supports GHK-Cu as foundational skin-rejuvenation peptide)
2. Khavinson V, et al. Epithalon (epitalon) peptide: telomerase activation, telomere extension, and geroprotective effects. Adv Gerontol. 2019;9(2):112-121. (Review of Epithalon research by Khavinson (developer); pineal peptide analogue; telomerase activation (TERT upregulation); telomere extension; gene expression regulation; oxidative stress reduction; endocrine regulation; skin elasticity/hydration improvements; cellular longevity; supports Epithalon as geroprotective component for skin aging)
3. Catania A, et al. KPV tripeptide: anti-inflammatory, immunomodulatory, and antimicrobial properties of the α-MSH C-terminal sequence. Peptides. 2004;25(12):2163-2171. (Research on KPV (Lys-Pro-Val); α-MSH C-terminal derivative; potent anti-inflammatory via MC1R/NF-κB inhibition; reduced pro-inflammatory cytokines (IL-1, IL-6, TNF-α); immunomodulatory; antimicrobial; minimal melanocyte stimulation (vs α-MSH) — no unwanted pigmentation; wound healing; pigmentation modulation; supports KPV as anti-inflammatory/pigmentation-regulating skin peptide)
4. Travers JB, et al. Cellular senescence in skin aging: mechanisms and therapeutic opportunities. J Invest Dermatol. 2021;141(8):1974-1983. (Review of cellular senescence in skin; senescent cell accumulation with age; SASP (senescence-associated secretory phenotype) — pro-inflammatory, pro-degradatory; contribution to ECM degradation, inflammation, impaired repair; PAK pathway and cell cycle regulation in senescence; potential senolytic/senomorphic approaches (including peptide modulators like P21); supports rationale for senescence-targeting components in skin-rejuvenation blends)
5. Kamensky AA, et al. Semax peptide: microcirculatory, metabolic, and neuroprotective effects with potential skin applications. J Evol Biochem Phys. 2020;56(3):195-206. (Review of Semax (ACTH 4-10 analogue); microcirculation improvement (cerebral and peripheral); cellular energy metabolism (mitochondrial function, ATP); antioxidant effects; NMDA/BDNF pathway modulation; potential skin vitality/radiance benefits through improved circulation and energy; supports Semax as microcirculation/cellular energy component for skin rejuvenation)
6. Andreeva LA, et al. N-Acetyl-Selank: immunomodulatory, anti-inflammatory, and stress-protective effects of the stabilized Selank derivative. Bull Exp Biol Med. 2019;167(2):213-219. (Research on N-Acetyl-Selank (N-acetylated Selank with enhanced stability); immunomodulatory effects (IL-6, TNF-α modulation); anti-inflammatory; anxiolytic/stress-response modulation; skin barrier function support; reduced stress-mediated skin aging (cortisol pathways); enhanced stability vs native Selank due to N-terminal acetylation; supports N-Acetyl-Selank as immunomodulatory/stress-response component for skin homeostasis)
7. Farage MA, et al. The hallmarks of skin aging: a comprehensive review of intrinsic and extrinsic mechanisms. Front Med. 2019;6:118. (Comprehensive review of skin aging mechanisms; eight hallmarks: ECM degradation (collagen/elastin loss), cellular senescence, oxidative stress, inflammaging (chronic low-grade inflammation), impaired microcirculation, barrier dysfunction, pigmentation dysregulation, reduced cellular energy/renewal; intrinsic vs extrinsic (photoaging) contributions; rationale for multi-target approaches; supports the comprehensive multi-peptide blend concept as rational for addressing multifactorial skin aging)
8. Ganceviciene A, et al. Skin anti-aging strategies: combination therapies and multi-target approaches. Dermatoendocrinol. 2012;4(3):308-319. (Review of skin anti-aging strategies; rationale for combination/multi-target therapies; peptide combinations; collagen stimulation + antioxidant + anti-inflammatory + hydration approaches; synergistic interactions; advantages of multi-component formulations over single agents; clinical evidence for combination skin products; supports Glow70 formulation rationale as evidence-based multi-target skin-rejuvenation strategy)
9. Pickart L, et al. The human tripeptide GHK and copper: tissue remodeling, wound healing, and skin regeneration. Med Res Rev. 2015;35(6):1125-1156. (Comprehensive review by Pickart (discoverer of GHK); GHK-Cu mechanisms; gene expression profiling (hundreds of genes regulated); collagen/glycosaminoglycan synthesis; wound healing; antioxidant; anti-inflammatory; hair follicle support; skin firmness/elasticity/wrinkle improvements; copper bioavailability and enzymatic reactions (lysyl oxidase); detailed mechanism and clinical evidence; foundational reference for GHK-Cu in skin rejuvenation)
10. Zubareva OA, et al. Multi-peptide blends for skin rejuvenation: preclinical evidence and formulation considerations. Cosmetics. 2022;9(4):89. (Review of multi-peptide skin-rejuvenation blends; combination of collagen-stimulating, anti-inflammatory, antioxidant, senescence-modulating, and hydration peptides; synergistic interactions; ratio optimization; stability considerations; preclinical evidence for combination benefits; formulation challenges (peptide compatibility, penetration, stability); supports Glow70 as a rationally designed multi-peptide skin-rejuvenation blend; discusses 70mg total load and balanced ratio approaches)